Evidence map›Paper›PMID 36518770›Full record

Trial reportFrontiers in immunology2022

Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients.

Christophe Masset, Jacques Dantal, Jean-Paul Soulillou, Alexandre Walencik, Florent Delbos, Sophie Brouard, Magali Giral, Nantes DIVAT Consortium

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Rise of a CD27European journal of immunology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Christophe MassetInstitut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalo-Universitaire (CHU) Nantes, Nantes, France.
Jacques DantalInstitut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalo-Universitaire (CHU) Nantes, Nantes, France.
Jean-Paul SoulillouInstitut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalo-Universitaire (CHU) Nantes, Nantes, France.
Alexandre WalencikLaboratoire d'immunologie et HLA Etablissement Français du Sang, Nantes, France.
Florent DelbosLaboratoire d'immunologie et HLA Etablissement Français du Sang, Nantes, France.
Sophie BrouardInstitut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalo-Universitaire (CHU) Nantes, Nantes, France.
Magali GiralInstitut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalo-Universitaire (CHU) Nantes, Nantes, France.
Nantes DIVAT Consortium
Établissement Français du Sang · FRInserm · FRNantes Université · FRInstitut de Transplantation Urologie en Nephrologie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whilst calcineurin inhibitors (CNI) are the cornerstone of immunosuppressive maintenance therapy in kidney transplantation, several studies have investigated the safety of CNI withdrawal in order to avoid their numerous side effects. In this context, we performed several years ago a clinical randomized trial evaluating CNI weaning in stable kidney transplant recipients without anti-HLA immunization. The trial was interrupted prematurely due to a high number of

Indexed as

Graft RejectionTacrolimusCalcineurin InhibitorsHumansNeoplasm Recurrence, LocalRetrospective StudiesWeaningCalcineurin InhibitorsTacrolimusallograft rejectioncalcineurin inhibitor withdrawalcase reportdonor specific antibodieskidney transplantation

Identifiers

PMID36518770
PMCPMC9744190
OpenAlexW4310218175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.